scholarly journals The Long-Term Outcome of CyberKnife-Based Stereotactic Radiotherapy for Intra/ Extracranial Non-Vestibular Schwannomas: A Single-Center Experience

2022 ◽  
Author(s):  
Sukwoo Hong ◽  
Kenji Kagawa ◽  
Kengo Sato ◽  
Ryutaro Nomura ◽  
Shunsuke Ichi
Keyword(s):  
Stereotactic Radiotherapy ◽  
Significant Risk ◽  
Progression Free Survival ◽  
Target Volume ◽  
Vestibular Schwannomas ◽  
P Value ◽  
Tumor Extension ◽  
Term Outcome ◽  
Long Term Outcome

Abstract The long-term outcomes of CyberKnife-based hypofractionated stereotactic radiotherapy (SRT) for intra/ extracranial non-vestibular schwannomas (nVS) need to be accumulated. Patients who received SRT by CyberKnife for nVS from 2010 to 2019 were retrospectively reviewed. A total of 45 patients with nVS were identified. The mean age was 53 (± 18) years old, and 23 patients (51%) were female. Twenty-nine patients (64%) had previous procedures. As for the tumor extension, 22 (49%) nVS were classified as primary intracranial, five (11%) were classified as intra/ extracranial (dumbbell shape), and 18 (40%) were classified as primary extracranial. The median prescribed dose, covering 95% of the planning target volume, was 21 (IQR 21 – 25) Gy, and the median target volume was 7 (IQR 3.6-13.1) cm3. The local control rate of nVS for patients without neurofibromatosis type 2 (NF2) was 100%. Old age (OR 0.92, p-value 0.03) and previous surgery (OR 0.02, p-value 0.02) were significant risk factors for no symptomatic improvement. The progression-free survival was 74 (±33) months clinically and 69 (IQR 36 – 94) months radiologically. During follow-up, two cases (4%) with NF2 resulted in treatment failure, 13 cases (41%) resulted in transient tumor expansion (TTE), 10 (22%) suffered from transient adverse radiation effect (ARE), and two (4%) resulted in permanent ARE. Hypofractionated SRT by CyberKnife for head, neck, and spine nVS was an effective treatment regardless of tumor extension relative to the cranium. Although the risk of permanent ARE was low, some patients experienced transient clinical worsening due to TTE.

scholarly journals The Long-term Outcome of CyberKnife-Based Stereotactic Radiotherapy for Intra/ Extracranial Non-Vestibular Schwannomas: A Single-Center Experience

2021 ◽  
Author(s):  
Sukwoo Hong ◽  
Kenji Kagawa ◽  
Kengo Sato ◽  
Ryutaro Nomura ◽  
Shunsuke Ichi
Keyword(s):  
Stereotactic Radiotherapy ◽  
Significant Risk ◽  
Progression Free Survival ◽  
Target Volume ◽  
Vestibular Schwannomas ◽  
P Value ◽  
Tumor Extension ◽  
Term Outcome ◽  
Long Term Outcome

Abstract Background The long-term outcomes of CyberKnife-based hypofractionated stereotactic radiotherapy (SRT) for intra/ extracranial non-vestibular schwannomas (nVS) need to be accumulated. Method Patients who received SRT by CyberKnife for nVS from 2010 to 2019 were retrospectively reviewed. Results A total of 45 patients with nVS were identified. The mean age was 53 (± 18) years old, and 23 patients (51%) were female. Twenty-nine patients (64%) had previous procedures. As for the tumor extension, 22 (49%) nVS were classified as primary intracranial, five (11%) were classified as intra/ extracranial (dumbbell shape), and 18 (40%) were classified as primary extracranial. The median prescribed dose, covering 95% of the planning target volume, was 21 (IQR 21 – 25) Gy, and the median target volume was 7 (IQR 3.6-13.1) cm3. The local control rate of nVS for patients without neurofibromatosis type 2 (NF2) was 100%. Old age (OR 0.92, p-value 0.03) and previous surgery (OR 0.02, p-value 0.02) were significant risk factors for no symptomatic improvement. The progression-free survival was 74 (±33) months clinically and 69 (IQR 36 – 94) months radiologically. During follow-up, two cases (4%) with NF2 resulted in treatment failure, 13 cases (41%) resulted in transient tumor expansion (TTE), 10 (22%) suffered from transient adverse radiation effect (ARE), and two (4%) resulted in permanent ARE. Conclusions Hypofractionated SRT for head, neck, and spine nVS was an effective treatment regardless of tumor extension relative to the cranium. Although the risk of permanent ARE was low, some patients experienced transient clinical worsening due to TTE.

scholarly journals The Long-Term Outcome of Cyberknife Therapy for Head and Neck Paraganglioma: Management Suggestion From a Single Center Experience

2021 ◽  
Author(s):  
Sukwoo Hong ◽  
Kenji Kagawa ◽  
Kengo Sato ◽  
Shunsuke Ichi
Keyword(s):  
Head And Neck ◽  
Symptom Control ◽  
Progression Free Survival ◽  
Target Volume ◽  
Symptom Improvement ◽  
Hormone Production ◽  
Term Outcome ◽  
Long Term Outcome

Abstract IntroductionTo analyze the long-term follow-up data of CyberKnife treatment (CKT) for head and neck paragangliomas (HNPGs). MethodsPatients who received CKT to HNPGs from 2010 to 2019 were retrospectively reviewed. ResultsA total of 34 HNPGs from 29 patients were identified. The mean age was 50 (± 16) years old, and 15 patients (52%) were female. Previous operation was done in 15 patients (55%). Four cases (14%) were functional in hormone production. According to Fisch classification, one case (3%) was B, 12 (42%) were C, 14 (48%) were D, and two cases (7%) were out of classification. The median prescribed dose covered 95% of the planning target volume was 2500 (IQR 2100 – 2600) cGy and the median target volume was 10 (IQR 5.8 – 21.3) cm3. The local control rate was 97%. The median progression-free survival was 66 (IQR 27.5 – 95.0) months and 93.8%, and 91.7% were free of tumor progression at five, and seven years respectively. During the follow-up, one case (3%) resulted in permanent facial nerve palsy (CTCAE 1, House-Brackmann grade II), and another case (3%) resulted in asymptomatic cerebellar radiation necrosis. Univariate and multivariate analysis showed no previous surgical history (OR 10.3, 95% CI 1.5 – 69.3, p = 0.02) was a positive predictor of symptom improvement. We devised a treatment flow-chart based on our finding. ConclusionsCKT for HNPGs was an effective treatment with little side effect over the long term and should be considered the first-line therapy for symptomatic nonfunctional HNPGs for better symptom control.

scholarly journals The long-term outcome of CyberKnife therapy for head and neck paraganglioma: Management suggestion from a single center experience

2021 ◽  
Author(s):  
Sukwoo Hong ◽  
Kenji Kagawa ◽  
Kengo Sato ◽  
Shunsuke Ichi
Keyword(s):  
Head And Neck ◽  
Symptom Control ◽  
Progression Free Survival ◽  
Target Volume ◽  
Symptom Improvement ◽  
Hormone Production ◽  
Term Outcome ◽  
Long Term Outcome

Abstract To analyze the long-term follow-up data of CyberKnife treatment (CKT) for head and neck paragangliomas (HNPGs). Patients who received CKT to HNPGs from 2010 to 2019 were retrospectively reviewed. A total of 34 HNPGs from 29 patients were identified. The mean age was 50 (± 16) years old, and 15 patients (52%) were female. Previous operation was done in 15 patients (55%). Four cases (14%) were functional in hormone production. According to Fisch classification, one case (3%) was B, 12 (42%) were C, 14 (48%) were D, and two cases (7%) were out of classification. The median prescribed dose covered 95% of the planning target volume was 2500 (IQR 2100–2600) cGy and the median target volume was 10 (IQR 5.8–21.3) cm3. The local control rate was 97%. The median progression-free survival was 66 (IQR 28–95) months and 96% were free of tumor progression at eight years. During the follow-up, one case (3%) resulted in permanent facial nerve palsy (House-Brackmann grade II), and another case (3%) resulted in asymptomatic cerebellar radiation necrosis. Univariate and multivariate analysis showed no previous surgical history (OR 8.58, 95% CI 1.2–59.7, p = 0.03) was a positive predictor of symptom improvement. We devised a treatment flow-chart based on our finding. CKT for HNPGs was an effective treatment with little side effect over the long term and may have a role in the first-line therapy especially for symptomatic nonfunctional HNPGs for better symptom control.

scholarly journals LGG-06. LONG-TERM OUTCOME OF NEWLY DIAGNOSED LOW GRADE GLIOMA

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii367-iii367
Author(s):  
Nongnuch Sirachainan ◽  
Attaporn Boongerd ◽  
Samart Pakakasama ◽  
Usanarat Anurathapan ◽  
Ake Hansasuta ◽  
...  
Keyword(s):  
Surgical Management ◽  
Progression Free Survival ◽  
Low Grade Glioma ◽  
Low Grade ◽  
Newly Diagnosed ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Common Location ◽  
Suprasellar Region

Abstract INTRODUCTION Low grade glioma (LGG) is the most common central nervous system (CNS) tumor in children accounted for 30–50%. Regarding benign characteristic of disease, surgical management remains the mainstay of treatment. However, surgical approach is limited in some conditions such as location at brainstem or infiltrative tumor. Chemotherapy and radiation treatments have been included in order to control tumor progression. The 5-years survival rate is approach 90% especially in patients who receive complete resection. However, the outcome of children with LGG in low to middle income is limited. Therefore, the aim of the study was to determine long-term outcome of children with newly diagnosed LGG. METHODS A retrospective study enrolled children aged <18 years who were newly diagnosed LGG during January 2006- December 2019. Diagnosis of LGG was confirmed by histological findings of grade I and II according to WHO criteria. RESULTS A total of 40 patients, female to male ratio was 1:1.35 and mean (SD) for age was 6.7 (4.0) years. The most common location was optic chiasmatic pathway (42.5%), followed by suprasellar region (25.0%). Sixty percent of patients received at least partial tumor removal. Chemotherapy and radiation had been used in 70% and 10.0% respectively. The 10-year progression free survival was 74.1±11.4% and overall survival was 96.2±3.8%. SUMMARY: Treatment of Pediatric LGG mainly required surgical management, however, chemotherapy and radiation had been used in progressive disease. The outcome was excellent.

Long-term outcomes in children with glioblastoma

2010 ◽  
Vol 6 (2) ◽  
pp. 145-149 ◽  
Author(s):  
Kyung Sun Song ◽  
Ji Hoon Phi ◽  
Byung-Kyu Cho ◽  
Kyu-Chang Wang ◽  
Ji Yeoun Lee ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Progression Free Survival ◽  
Radical Resection ◽  
Tumor Location ◽  
Recurrent Glioblastoma ◽  
Subtotal Resection ◽  
Long Term Outcomes ◽  
Term Outcome ◽  
Long Term Outcome

Object Glioblastoma is the most common primary malignant brain tumor; however, glioblastoma in children is less common than in adults, and little is known about its clinical outcome in children. The authors evaluated the long-term outcome of glioblastoma in children. Methods Twenty-seven children were confirmed to have harbored a glioblastoma between 1985 and 2007. The clinical features and treatment outcomes were reviewed retrospectively. All patients underwent resection; complete resection was performed in 12 patients (44%), subtotal resection in 12 patients (44%), and biopsy in 3 patients (11%). Twenty-four patients (89%) had radiation therapy, and 14 (52%) patients received chemotherapy plus radiation therapy. Among the latter, 5 patients had radiation therapy concurrent with temozolomide chemotherapy. Four patients with small-size recurrent glioblastoma received stereotactic radiosurgery. Results The median overall survival (OS) was 43 months, and the median progression-free survival was 12 months. The OS rate was 67% at 1 year, 52% at 2 years, and 40% at 5 years. The median OS was significantly associated with tumor location (52 months for superficially located tumors vs 7 months for deeply located tumors; p = 0.017) and extent of removal (106 months for completely resected tumors vs 11 months for incompletely resected tumors; p < 0.0001). Conclusions The prognosis of glioblastoma is better in children than in adults. Radical resection followed by concurrent chemoradiation therapy may be the initial treatment of choice.

scholarly journals Fractionated stereotactic radiotherapy for uveal melanoma: Long‐term outcome and control rates

2021 ◽  
Author(s):  
Jackelien G. M. van Beek ◽  
Caroline M. van Rij ◽  
Sara J. Baart ◽  
Serdar Yavuzyigitoglu ◽  
Michael J. Bergmann ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Stereotactic Radiotherapy ◽  
Fractionated Stereotactic Radiotherapy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
And Control

scholarly journals Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience

Blood ◽  
1996 ◽  
Vol 88 (6) ◽  
pp. 1954-1959 ◽  
Author(s):  
MS Tallman ◽  
D Hakimian ◽  
AW Rademaker ◽  
C Zanzig ◽  
E Wollins ◽  
...  
Keyword(s):  
Relapse Rate ◽  
Hairy Cell Leukemia ◽  
Progression Free Survival ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Prior Therapy ◽  
Long Term Follow Up

Although 2-chlorodeoxyadenosine (2-CdA) is effective in inducing complete remissions (CRs) in the majority of patients with hairy cell leukemia (HCL), neither the actual relapse rate, the clinical factors that may predict relapse, the long-term outcome, nor the response rate to re-treatment at relapse has been clearly determined. Fifty-two consecutive patients with previously untreated or treated HCL were treated with 2-CdA at a dose of 0.1 mg/kg/d by continuous intravenous infusion for 7 days. Of 50 assessable patients, 40 (80%) achieved CR, and 9 (18%) achieved partial remission (PR). A total of 7 patients (14%) have relapsed, at a median duration of 24 months (range, 12 to 44). Of the 7 relapsed patients, 5 were re-treated with a second cycle of 2-CdA; 2 achieved a second CR and 3 attained a PR. The progression- free survival (PFS) rate is 72% at 4 years for all 52 patients and 83% for patients achieving CR. The overall survival (OS) rate is 86% at 4 years. Only prior therapy was predictive of relapse. The majority of patients achieve durable CRs with a single cycle of 2-CdA. The relapse rate is low and the long-term prognosis is excellent. The few patients who relapse can attain second remissions after re-treatment with 2-CdA.

scholarly journals O2.07 * FIRST 100 VESTIBULAR SCHWANNOMAS TREATED WITH GAMMA KNIFE IN SPAIN: LONG-TERM OUTCOME

2014 ◽  
Vol 16 (suppl 2) ◽  
pp. ii4-ii4
Author(s):  
P. de Andres ◽  
A. L. Presti ◽  
M. E. Kusak ◽  
N. Martinez ◽  
J. M. de Campos ◽  
...  
Keyword(s):  
Gamma Knife ◽  
Vestibular Schwannomas ◽  
Term Outcome ◽  
Long Term Outcome
Sign in / Sign up

Export Citation Format

Share Document